Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228265 · ClinicalTrials.gov registry record
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
A clinical trial, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- 41
- Enrollment target
NCT02228265 is a clinical trial that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 41 participants.
The verdict
NCT02228265 has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- 41 participants
- Enrollment target
Study Summary
This research trial studies molecular features and pathways in predicting drug resistance in patients with castration-resistant prostate cancer that has spread to other parts of the body and who are receiving enzalutamide. Studying samples of blood and tissue in the laboratory from patients receiving enzalutamide may help doctors learn more about molecular features and pathways that may cause prostate cancer to be resistant to the drug.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Cytology Specimen Collection Procedure
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2013-03-12 |
| Est. Completion | 2020-02-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02228265
The ClinicalTrials.gov registry entry for NCT02228265 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02228265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02228265 about?
NCT02228265 is a clinical study titled "Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide". This research trial studies molecular features and pathways in predicting drug resistance in patients with castration-resistant prostate cancer that has spread to other parts of the body and who are receiving enzalutamide. Studying samples of blood and tissue in the laboratory from patients receivin...
What is the current status of trial NCT02228265?
This trial is currently completed. The enrollment target is 41 participants. The study started on 2013-03-12. Estimated completion is 2020-02-27.
What interventions are being tested in trial NCT02228265?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02228265?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.